Reuters Health Information: Gilead's hep B drug as effective as Viread but safer
Gilead's hep B drug as effective as Viread but safer
Last Updated: 2016-01-05
By Reuters Staff
(Reuters) - Gilead Sciences Inc said its experimental
hepatitis B drug proved as effective as but safer than its
approved treatment, Viread, in two late-stage studies.
The once-daily drug, tenofovir alafenamide (TAF), showed
improved renal and bone safety compared with Viread (tenofovir
disoproxil fumarate), Gilead said on Tuesday.
The company plans to seek regulatory approval for TAF in the
United States and Europe in the first quarter of 2016.
The drugmaker said in September that TAF was found safer
than but as effective as its popular HIV drug, Truvada
(tenofovir disoproxil/emtricitabine), in a late-stage study.
Patients given TAF experienced significantly lower loss of
bone mineral density and kidney function than those on Truvada.
Gilead is developing TAF as a safer replacement for Viread
and Truvada.
Stay Informed!
